In the past few years, knowledge on the resistance to therapy with monoclonal antibodies in colorectal cancer has evidenced the role of mutations in a series of proteins involved in the epidermal growth factor receptor (EGFR) pathway. KRAS mutations can influence the response to therapy, as demonstrated by clinical utilization of cetuximab and panitumumab that are indicated only in KRAS wild-type colorectal cancer. Recently, it has been demonstrated that the mutational status of other proteins like NRAS, BRAF, PI3K or alterations in EGFR and other tyrosine kinase receptors are involved both in primary and secondary resistance to anti-EGFR monoclonal antibodies and could predict the patient response and survival. Many therapeutic strategies have been studied to overcome resistance to these drugs, which include the use of drugs directed against proteins involved in the intracellular signalling pathway of EGFR, such as inhibitors of MEK, BRAF, PI3K/mTOR, or directed against other tyrosine kinase receptors such as MET and HER2. This review will analyse recent strategies utilized to overcome resistance to anti-EGFR monoclonal antibodies in colorectal cancer.

Strategies to overcome resistance to anti-EGFR monoclonal antibodies in colorectal cancer

BOSCARO, Valentina
First
;
GALLICCHIO, Margherita
Last
2016-01-01

Abstract

In the past few years, knowledge on the resistance to therapy with monoclonal antibodies in colorectal cancer has evidenced the role of mutations in a series of proteins involved in the epidermal growth factor receptor (EGFR) pathway. KRAS mutations can influence the response to therapy, as demonstrated by clinical utilization of cetuximab and panitumumab that are indicated only in KRAS wild-type colorectal cancer. Recently, it has been demonstrated that the mutational status of other proteins like NRAS, BRAF, PI3K or alterations in EGFR and other tyrosine kinase receptors are involved both in primary and secondary resistance to anti-EGFR monoclonal antibodies and could predict the patient response and survival. Many therapeutic strategies have been studied to overcome resistance to these drugs, which include the use of drugs directed against proteins involved in the intracellular signalling pathway of EGFR, such as inhibitors of MEK, BRAF, PI3K/mTOR, or directed against other tyrosine kinase receptors such as MET and HER2. This review will analyse recent strategies utilized to overcome resistance to anti-EGFR monoclonal antibodies in colorectal cancer.
2016
20
87
98
http://www.researchtrends.net/tia/article_pdf.asp?in=0&vn=20&tid=11&aid=5934
colorectal cancer, cetuximab, mAbs resistance, panitumumab
Boscaro, Valentina; Gallicchio, Margherita
File in questo prodotto:
File Dimensione Formato  
P 273_Vol 20_87-98.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 216.48 kB
Formato Adobe PDF
216.48 kB Adobe PDF Visualizza/Apri
Boscaro Curr Topics Pharm 2016 20.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 216.48 kB
Formato Adobe PDF
216.48 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1639184
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact